Antiretroviral therapy in Africa
Authors:
Abstract
HIV drug resistance Virus strains with reduced sensitivity to zidovudine, the first drug used to treat HIV infection, were first observed in 1989, three years after it was introduced.1 Subsequently, resistance to every currently licensed antiretroviral drug has been observed.2 Drug resistance within an individual patient is not confined to a single compound, and cross resistance between drugs of the same class is the rule rather than the exception.3 Drug resistance arises by natural selection, mutant strains being selected when the virus replicates in sub-limiting drug concentrations. The only way to prevent resistance is to use a drug regimen that reduces virus replication to virtually zero (commonly equated with a plasma virus load below 50 RNA copies/ml). In this circumstance, the probability of a mutant arising to all the drugs used in a highly active antiretroviral therapy regimen is very low. However, should the concentrations of the drugs fall sufficiently to allow appreciable virus replication, the chances of a resistant mutant being selected increase. The concentration of antiretroviral drugs at their active site varies for several reasons including eating habits, exercise habits, and concurrent illnesses. However, the main cause of variation is the timing of the dosing schedule. Concentrations of the drug peak shortly after a dose is taken and then wane until the next dose is taken. Antiretroviral regimens are designed so that the trough concentrations of the drugs are never sufficient to allow appreciable virus replication.4 The longer a dose is delayed, the lower the concentration falls and the more virus replication occurs. Thus, intermittent therapy and poor adherence are the principal factors leading to drug resistance. Although most resistant strains are poor at replicating and do not persist in the absence of drugs,5 viral variants are archived as provirus in long lived memory T cells6 and will be rapidly selected when therapy is resumed. Zambian patient in a homebased care project for AIDS sufferers Credit: PEP BONET/PANOS The only sure way to avoid the development of drug resistance is to adhere strictly to therapy. Failure to completely suppress virus replication has been shown to result in the development of resistance even at high levels of adherence (> 92%).7Keywords
This publication has 16 references indexed in Scilit:
- High levels of adherence do not prevent accumulation of HIV drug resistance mutationsAIDS, 2003
- Adherence is not a barrier to successful antiretroviral therapy in South AfricaAIDS, 2003
- Fitness of drug resistant HIV-1: methodology and clinical implicationsDrug Resistance Updates, 2002
- Antiretroviral-Drug Resistance among Patients Recently Infected with HIVNew England Journal of Medicine, 2002
- The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up studyAIDS, 2002
- Impact of drug resistance mutations on virologic response to salvage therapyAIDS, 1999
- Randomised controlled trial of self-supervised and directly observed treatment of tuberculosisThe Lancet, 1998
- Recovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma ViremiaScience, 1997
- HIV viral load markers in clinical practiceNature Medicine, 1996
- HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged TherapyScience, 1989